医学
淋巴水肿
蜂窝织炎
继发性淋巴水肿
显微外科
淋巴系统
纤维化
外科
脂肪团
内科学
病理
乳腺癌
癌症
作者
Marco Pappalardo,Chia‐Yu Lin,Chieh Lin,Kevin C. Chung,Ming‐Huei Cheng
出处
期刊:Annals of Surgery
[Lippincott Williams & Wilkins]
日期:2025-08-01
卷期号:282 (4): 639-649
被引量:1
标识
DOI:10.1097/sla.0000000000006860
摘要
Objective: To assess the effect of complete decongestive therapy (CDT) and lymphedema microsurgery (LM) on the natural progression of extremity lymphedema. Background: The natural progression of extremity lymphedema includes interstitial lymph accumulation, frequent cellulitis, adipose deposition, and fibrosis, which remain unexplored. Methods: Prospectively collected data of patients with extremity lymphedema managed with either CDT (61 patients) or LM (118 patients) with a follow-up of 2 years between November 2011 and September 2019 were analyzed. The primary outcomes included Taiwan lymphoscintigraphy staging (TLS) to assess lymphatic drainage; episodes of cellulitis for infection; limb circumferential and volumetric differences for adipogenesis; and tissue softness for fibrosis. The secondary outcome was a lymphedema-specific quality-of-life (LYMQOL) questionnaire. Results: At 1-year follow-up, the LM group demonstrated significant improvements in mean TLS (3.77±1.48 vs 2.67±1.33, P <0.0001), and volumetric difference (43.2±25.8% vs 31.7%±21.7%, P =0.00025). Moreover, at 2-year follow-up, the LM group exhibited a significant reduction of episodes of cellulitis (2.39±2.05 vs 0.77±1.04, P <0.0001), circumferential difference (23.4±11.3% vs 14.3±11.0%, P <0.0001), and tissue-softness grade (2.41±1.15 vs 1.42±0.633, P <0.0001). Improvements were observed across all 5 LYMQOL domains at 1 and 2 years in patients with LM (all P <0.0001). No significant improvements in the primary or secondary outcomes were noted in the CDT group. Conclusions: The LM group had significantly increased lymphatic drainage, decreased episodes of cellulitis and adipogenesis, reduced fibrosis, and improved quality of life compared with the CDT group.
科研通智能强力驱动
Strongly Powered by AbleSci AI